Daisuke Tsuji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daisuke Tsuji has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Kohji Itoh
Department of Medicinal Biotechnology, Graduate School of Pharmaceutical Sciences, Tokushima University, 1-78-1 Sho-machi, Tokushima 770-8505, Japan; Department of Medicinal Biotechnology, Faculty of Pharmaceutical Sciences, Tokushima University, 1-78-1 Sho-machi, Tokushima 770-8505, Japan; Division of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan
6 shared publications - Akira Shigenaga
Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima 729-0292, Japan
2 shared publications Ken Sakamoto
Institute of Health Bioscience and Graduate School of Pharmaceutical Sciences, The University of Tokushima, Shomachi, Tokushima 770-8505 (Japan)
2 shared publications- Kohei Sato
Shizuoka University
2 shared publications - Ahmad Azlina
Affiliation School of Dental Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia
1 shared publication - Akira Otaka
Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, Japan
1 shared publication
Latest Publications
- 13 June 2013
- Published by Wiley in Angewandte Chemie
- Vol. 125 (30) , 8009-8013
Chemical Synthesis of Biologically Active Monoglycosylated GM2-Activator Protein Analogue UsingN-Sulfanylethylanilide Peptide
- 13 June 2013
- Published by Wiley in Angewandte Chemie
- Vol. 125 (30) , 8009-8013
Chemical Synthesis of Biologically Active Monoglycosylated GM2-Activator Protein Analogue UsingN-Sulfanylethylanilide Peptide
- Open Access
- 27 February 2013
- Published by IntechOpen
Molecular Therapy for Lysosomal Storage Diseases
Molecular Therapy for Lysosomal Storage Diseases | InTechOpen, Published on: 2013-02-27. Authors: Daisuke Tsuji and Kohji Itoh
- 27 February 2013
- Published by IntechOpen
Open AccessMolecular Therapy for Lysosomal Storage Diseases
Molecular Therapy for Lysosomal Storage Diseases | InTechOpen, Published on: 2013-02-27. Authors: Daisuke Tsuji and Kohji Itoh
- 1 February 2013
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 133 (2) , 269-274
Molecular Pathogenesis and Therapeutic Approach of GM2 Gangliosidosis
Tay-Sachs and Sandhoff diseases (GM2 gangliosidoses) are autosomal recessive lysosomal storage diseases caused by gene mutations in HEXA and HEXB, each encoding human lysosomal β-hexosaminidase α-subunits and β-subunits, respectively. In Tay-Sachs disease, excessive accumulation of GM2 ganglioside (GM2), mainly in the central nervous system, is caused by a deficiency of the HexA isozyme (αβ heterodimer), resulting in progressive neurologic disorders. In Sandhoff disease, combined deficiencies of HexA and HexB (ββ homodimer) cause not only the accumulation of GM2 but also of oligosaccharides carrying terminal N-acetylhexosamine residues (GlcNAc-oligosaccharides), resulting in systemic manifestations including hepatosplenomegaly as well as neurologic symptoms. Hence there is little clinically effective treatment for these GM2 gangliosidoses. Recent studies on the molecular pathogenesis in Sandhoff disease patients and disease model mice have shown the involvement of microglial activation and chemokine induction in neuroinflammation and neurodegeneration in this disease. Experimental and therapeutic approaches, including recombinant enzyme replacement, have been performed using Sandhoff disease model mice, suggesting the future application of novel techniques to treat GM2 gangliosidoses (Hex deficiencies), including Sandhoff disease as well as Tay-Sachs disease. In this study, we isolated astrocytes and microglia from the neonatal brain of Sandhoff disease model mice and demonstrated abnormalities of glial cells. Moreover, we demonstrated the therapeutic effect of an intracerebroventricular administration of novel recombinant human HexA carrying a high content of M6P residue in Sandhoff disease model mice.
- 1 February 2013
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 133 (2) , 269-274
Molecular Pathogenesis and Therapeutic Approach of GM2 Gangliosidosis
Tay-Sachs and Sandhoff diseases (GM2 gangliosidoses) are autosomal recessive lysosomal storage diseases caused by gene mutations in HEXA and HEXB, each encoding human lysosomal β-hexosaminidase α-subunits and β-subunits, respectively. In Tay-Sachs disease, excessive accumulation of GM2 ganglioside (GM2), mainly in the central nervous system, is caused by a deficiency of the HexA isozyme (αβ heterodimer), resulting in progressive neurologic disorders. In Sandhoff disease, combined deficiencies of HexA and HexB (ββ homodimer) cause not only the accumulation of GM2 but also of oligosaccharides carrying terminal N-acetylhexosamine residues (GlcNAc-oligosaccharides), resulting in systemic manifestations including hepatosplenomegaly as well as neurologic symptoms. Hence there is little clinically effective treatment for these GM2 gangliosidoses. Recent studies on the molecular pathogenesis in Sandhoff disease patients and disease model mice have shown the involvement of microglial activation and chemokine induction in neuroinflammation and neurodegeneration in this disease. Experimental and therapeutic approaches, including recombinant enzyme replacement, have been performed using Sandhoff disease model mice, suggesting the future application of novel techniques to treat GM2 gangliosidoses (Hex deficiencies), including Sandhoff disease as well as Tay-Sachs disease. In this study, we isolated astrocytes and microglia from the neonatal brain of Sandhoff disease model mice and demonstrated abnormalities of glial cells. Moreover, we demonstrated the therapeutic effect of an intracerebroventricular administration of novel recombinant human HexA carrying a high content of M6P residue in Sandhoff disease model mice.
- 20 May 2011
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (5) , 1061-1068
Thymic involution and corticosterone level in Sandhoff disease model mice: new aspects the pathogenesis of GM2 gangliosidosis
Sandhoff disease (SD) is a lysosomal disease caused by a mutation of the HEXB gene associated with excessive accumulation of GM2 ganglioside (GM2) in lysosomes and neurological manifestations. Production of autoantibodies against the accumulated gangliosides has been reported to be involved in the progressive pathogenesis of GM2 gangliosidosis, although the underlying mechanism has not been fully elucidated. The thymus is the key organ in the acquired immune system including the development of autoantibodies. We showed here that thymic involution and an increase in cell death in the organ occur in SD model mice at a late stage of the pathogenesis. Dramatic increases in the populations of Annexin-V+ cells and terminal deoxynucletidyl transferase dUTP nick end labeling (TUNEL) + cells were observed throughout the thymuses of 15-week old SD mice. Enhanced caspase-3/7 activation, but not that of caspase-1/4, -6 ,-8, or −9, was also demonstrated. Furthermore, the serum level of corticosterone, a potent inducer of apoptosis of thymocytes, was elevated during the same period of apoptosis. Our studies suggested that an increase in endocrine corticosterone may be one of the causes that accelerate the apoptosis of thymocytes leading to thymic involution in GM2 gangliosidosis, and thus can be used as a disease marker for evaluation of the thymic condition and disease progression.
- 20 May 2011
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (5) , 1061-1068
Thymic involution and corticosterone level in Sandhoff disease model mice: new aspects the pathogenesis of GM2 gangliosidosis
Sandhoff disease (SD) is a lysosomal disease caused by a mutation of the HEXB gene associated with excessive accumulation of GM2 ganglioside (GM2) in lysosomes and neurological manifestations. Production of autoantibodies against the accumulated gangliosides has been reported to be involved in the progressive pathogenesis of GM2 gangliosidosis, although the underlying mechanism has not been fully elucidated. The thymus is the key organ in the acquired immune system including the development of autoantibodies. We showed here that thymic involution and an increase in cell death in the organ occur in SD model mice at a late stage of the pathogenesis. Dramatic increases in the populations of Annexin-V+ cells and terminal deoxynucletidyl transferase dUTP nick end labeling (TUNEL) + cells were observed throughout the thymuses of 15-week old SD mice. Enhanced caspase-3/7 activation, but not that of caspase-1/4, -6 ,-8, or −9, was also demonstrated. Furthermore, the serum level of corticosterone, a potent inducer of apoptosis of thymocytes, was elevated during the same period of apoptosis. Our studies suggested that an increase in endocrine corticosterone may be one of the causes that accelerate the apoptosis of thymocytes leading to thymic involution in GM2 gangliosidosis, and thus can be used as a disease marker for evaluation of the thymic condition and disease progression.
- 25 February 2011
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 40 (8) , 651-658
Induction of Sca-1 in the duct cells of the mouse submandibular gland by obstruction of the main excretory duct
- 25 February 2011
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 40 (8) , 651-658
Induction of Sca-1 in the duct cells of the mouse submandibular gland by obstruction of the main excretory duct
- 1 July 2007
- Vol. 79 (7) , 678-82
[Molecular pathogenesis and therapeutic targets of lysosomal diseases].
- 1 July 2007
- Vol. 79 (7) , 678-82
[Molecular pathogenesis and therapeutic targets of lysosomal diseases].